East Bay

East Bay Therapeutics was a biopharmaceutical company focused on the development of transformative therapies for patients with rare diseases. Founded in 2017 and based in the San Francisco Bay Area, the company gained significant industry attention in 2018 through a strategic collaboration with AstraZeneca to develop a portfolio of preclinical rare disease assets. Led by experienced biotech executive Dr. Peter Lu, the company aimed to leverage its expertise in rare disease drug development to advance these licensed programs toward clinical trials. However, the company has been largely inactive since approximately 2021, with its leadership moving to other ventures and its pipeline status remaining undisclosed.